Figure 3.

Recent developments and applications of liquid biopsy in neurological disease contexts. There is an unmet need for diagnostic, prognostic, and treatment-monitoring liquid biomarkers in a wide variety of neurological diseases. Recent work highlighting potential cfDNA-based liquid biopsy targets in several common neurological conditions is summarized here. Conditions including (A) CNS tumours, (B) stroke, (C) traumatic brain injury, (D) Alzheimer’s disease, (E) epilepsy, (F) multiple sclerosis, and (G) neuroinfectious disease each have characteristics that could uniquely benefit from information provided by liquid biopsy.